Conduit Pharmaceuticals Inc. (CDT)

2.9500 -0.2600 (-8.10%) At close: 04:00PM EDT

Conduit Pharmaceuticals Inc.

4995 Murphy Canyon Road
Suite 300
San Diego, CA 92123
United States
760 471 8536
https://www.conduitpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 7

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. David Joszef Tapolczay	CEO & Director	419.8k	N/A	1959
Mr. Adam Sragovicz	Chief Financial Officer	116.67k	N/A	1970
Dr. Joanne M. Holland	Chief Scientific Officer	N/A	N/A	1975

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

Corporate Governance

Conduit Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.